At MacroGenics, a Reckoning Without a Script

On a February 2025 earnings call, MacroGenics chief medical officer Stephen Eck delivered a sentence that quietly ended an era. "Based on our internal review and assessment of TAMARACK efficacy and safety to-date," he said, "we've decided not to pursue further internal development of vobra duo and are exploring potential alternatives for partnering the program." The statement was clinical in tone, but its implications were broad. Vobra duo was the most advanced wholly owned pipeline asset in a company that, after two decades, had only ever brought one wholly owned drug to market on its own.

The decision did not come from a vacuum. Vobra duo was a bispecific antibody targeting B7-H3 and CD3, designed to redirect T cells against tumors expressing B7-H3. That target threads through much of MacroGenics' history: the same protein was the basis for enoblituzumab, a monoclonal antibody the company had already discontinued, and for MGC026, an antibody-drug conjugate still in clinical development. B7-H3 has been the company's central scientific bet for years, and the vobra duo halt was the second time the target had failed to generate a viable wholly owned late-stage candidate.

The TAMARACK trial, which had been evaluating vobra duo in patients with select advanced solid tumors, did not produce the sort of data that would justify the development expense ahead. MacroGenics did not release detailed efficacy or safety figures alongside the announcement, but the decision to stop internal investment at the phase 2 stage signals that the risk-reward calculus no longer supported continued spending. The program is not dead; the company is looking for a partner willing to take it forward. But for a firm of MacroGenics' size, a partnered asset is not a pipeline driver. It is a potential royalty stream, years away.

The only wholly owned product MacroGenics ever brought to market on its own was MARGENZA, a monoclonal antibody targeting HER2. The FDA approved it in December 2020 for use in combination with chemotherapy for patients with metastatic HER2-positive breast cancer who had received two or more prior anti-HER2 regimens. It was a narrow approval in a crowded field: trastuzumab, pertuzumab, and trastuzumab deruxtecan had already established strong positions, and MARGENZA entered a market where differentiation was difficult.

Commercial performance reflected that reality. By the fourth quarter of 2024, MacroGenics had concluded that the drug's revenue trajectory did not justify the cost of maintaining its own commercial infrastructure. In October 2024, the company sold global rights to MARGENZA to TerSera Therapeutics for a $40 million upfront payment and up to $35 million in additional sales milestones. The deal was not transformative for the balance sheet, but it was clarifying: MacroGenics was exiting the business of selling its own drugs.

The sale also stripped away a layer of expense. Research and development costs for FY2024 were $177.2 million, up from $166.6 million in FY2023, but that increase masked a shift in composition. Costs related to margetuximab, the molecule behind MARGENZA, declined, while spending on MGC028, the preclinical ADC pipeline, and lorigerlimab increased. The company was reallocating resources away from its only approved product and toward earlier-stage programs, a bet that depends on the science working before the cash runs out.

MacroGenics incorporated in 2000, the same year Scott Koenig left a senior role at MedImmune to start the company from a base in Rockville, Maryland. For nearly 25 years, Koenig was the company's public face, its scientific anchor, and its chief evangelist to investors. He led the company through its October 2013 IPO on the NASDAQ, through two decades of preclinical and clinical work, and through three FDA approvals: MARGENZA in 2020, ZYNYZ (a collaboration with the Chinese company Zai Lab) in 2022, and TZIELD (a partnership with Provention Bio, later acquired by Sanofi) in 2022.

But the latter two approvals, while significant, were not wholly owned. ZYNYZ, a bispecific antibody targeting CD3 and CD19, was developed in partnership with Zai Lab and is commercialized by them in China. TZIELD, an anti-CD3 monoclonal antibody that delays the onset of type 1 diabetes, was developed with Provention Bio and subsequently sold to Sanofi. Koenig's legacy includes three approved drugs, but only one that MacroGenics ever sold on its own, and that one has now been divested.

Koenig stepped down in early 2025. His departure was planned and orderly, but its timing alongside the vobra duo discontinuation gave the moment the weight of a structural break. Koenig had built the company in his own image: an integrated biotech with discovery, development, and commercial capabilities under one roof. The company that remains is smaller, less certain of its pipeline direction, and led by a new CEO.

MacroGenics reported total revenue of $150.0 million for FY2024, up sharply from $58.7 million in FY2023. The increase was driven primarily by an $85 million net increase in milestone revenue from the Incyte license agreement. The milestone reflected Incyte's progress in developing retifanlimab, a PD-1 inhibitor licensed to Incyte under a 2017 agreement, not anything MacroGenics did that quarter, and it created a revenue spike that masks the underlying operating reality.

Stripping out the Incyte milestone, the company's revenue picture is thinner. MARGENZA generated modest sales before its divestiture. Collaboration revenue from existing partnerships provides some base, but not enough to cover the $177.2 million in R&D spending and the $67.0 million net loss the company recorded in FY2024. The net loss was wider than the $9.1 million loss in FY2023, a swing driven by the fact that FY2023 had included a $50 million milestone from Sanofi, making the comparison unfavorable when the revenue composition changed.

The company ended 2024 with $201.7 million in cash, cash equivalents, and marketable securities. CFO James Karrels provided guidance on the Q4 2024 earnings call: "We anticipate that our cash, cash equivalents and marketable securities balance of $201.7 million as of December 31, 2024, plus additional projected and anticipated future payments from partners should extend our cash runway into the second half of 2026."

That runway assumption depends on additional partner payments materializing, which introduces its own risk. By March 31, 2026, cash and securities had already declined to $154.2 million, a burn rate that implies roughly 12 to 18 months of runway from the current position without a new milestone or financing event. The company is not in crisis, but it is running a clock.

With vobra duo consigned to the partnering list and MARGENZA sold, the pipeline that remains is narrower and earlier-stage. The most advanced wholly owned clinical program is now lorigerlimab, a bispecific antibody designed to block PD-1 and CTLA-4 simultaneously. It is being studied in multiple solid tumor indications, but it remains at an early enough stage that its registration path is not yet defined. Lorigerlimab carries the burden of a mechanism where others have tried and failed; combination checkpoint blockade is a crowded field, and the data will need to be distinctive.

The next candidate is MGC026, an antibody-drug conjugate that also targets B7-H3. It uses a TOP1i payload, a class of chemotherapeutic agents that inhibit topoisomerase I and have become a common ADC warhead. MGC026 is the last wholly owned B7-H3 program standing in the MacroGenics pipeline after vobra duo's discontinuation and enoblituzumab's earlier termination. The company's long bet on B7-H3 now rests on a single molecule, one that has not yet produced proof-of-concept data.

Beyond MGC026, the pipeline consists of preclinical ADC programs, including MGC028, which drove an increase in R&D costs in FY2024. The company has signaled a strategic pivot toward next-generation modalities, including bispecific antibodies and ADCs with novel payloads, but those programs are too early to evaluate. The pivot is real, but it is also a necessity: without a late-stage wholly owned program, MacroGenics cannot survive on partnerships alone.

The new CEO, Eric Blasius Risser, takes the helm at a moment that demands both strategic patience and financial discipline. He inherits a company with a strong scientific foundation, a culture built over two decades, and a pipeline that has not yet answered the fundamental question: can MacroGenics invent and commercialize a drug on its own? The vobra duo decision removed the nearest candidate for a yes. The clock is now running on the next one.